A kidney cancer diagnosis is life-altering, but advances in treatment have dramatically improved outcomes over the past two decades. Understanding the available treatment for kidney cancer at each stage empowers patients and families to make informed decisions, ask the right questions, and pursue the most effective care. The treatment landscape has expanded well beyond surgery alone, offering new hope even for advanced-stage disease. This article is general information, not medical advice, and it deliberately includes no drug dosing — treatment must be individualized by your care team.
According to the American Cancer Society, more than 80,000 new cases of kidney cancer are diagnosed in the United States each year. Renal cell carcinoma (RCC) accounts for roughly 90 percent of kidney cancers in adults. This guide covers the major treatment for kidney cancer options, how they relate to disease stage, expected outcomes, and practical guidance for navigating your care. Above all, keep in mind that survival and quality of life for kidney cancer have improved substantially, and many people do well — including some with advanced disease.
Understanding Kidney Cancer Stages
Treatment decisions depend heavily on the stage of kidney cancer at diagnosis. The staging system used by oncologists ranges from Stage I to Stage IV. The survival figures below are approximate, based on large historical populations, and are steadily improving with newer treatments:
- Stage I: Tumor is 7 cm or smaller and confined to the kidney. The five-year relative survival rate for localized disease is high — commonly cited at over 90 percent.
- Stage II: Tumor is larger than 7 cm but still confined to the kidney.
- Stage III: Cancer has spread to nearby lymph nodes, the renal vein, or surrounding tissues but not to distant organs. Five-year survival for regional disease is often cited around 70 percent.
- Stage IV: Cancer has spread to distant organs such as the lungs, bones, liver, or brain. Historical five-year survival figures for distant disease have been low (often cited around 15 percent), but these numbers predate today’s immunotherapy combinations and are improving.
Survival statistics are based on large populations and may not predict any one person’s outcome. Many factors influence prognosis, including the specific type of kidney cancer, tumor biology and risk group, overall health, and response to treatment. Ask your oncologist how the newest data apply to your particular situation rather than relying on older averages.
Surgery: The Primary Treatment for Early-Stage Kidney Cancer
Surgery remains the cornerstone of treatment for kidney cancer that has not spread to distant organs. The type of surgery depends on the tumor’s size, location, and the patient’s overall health.
Partial Nephrectomy (Nephron-Sparing Surgery)
This procedure removes the tumor and a small margin of healthy tissue while preserving the rest of the kidney. Partial nephrectomy is generally the preferred surgical approach for smaller, localized tumors when technically feasible. Benefits include:
- Preservation of kidney function
- Lower long-term risk of chronic kidney disease
- Comparable cancer control outcomes to radical nephrectomy for small tumors
Partial nephrectomy can be performed as open surgery, laparoscopically, or with robotic assistance. Robotic-assisted partial nephrectomy has become increasingly common due to shorter recovery times and improved precision, though the best approach depends on the tumor and the surgeon’s expertise.
Radical Nephrectomy
This procedure removes the entire kidney, sometimes along with surrounding fat, the adrenal gland, and nearby lymph nodes. Radical nephrectomy is typically considered for:
- Larger tumors (Stage II and some Stage III)
- Tumors that cannot be safely removed while preserving the kidney
- Tumors involving the renal vein or inferior vena cava
Most people can live a normal life with one functioning kidney, though monitoring of kidney function is important after surgery.
Active Surveillance
For very small tumors (often under about 3 cm) found incidentally in older patients or those with significant health conditions, active surveillance with regular imaging may be recommended instead of immediate surgery. This approach monitors the tumor with CT scans or MRIs at defined intervals and proceeds to treatment if the tumor shows concerning growth. It spares selected patients the risks of surgery when a small tumor may never threaten their health.
Ablation Therapies
For small kidney tumors in patients who are not good surgical candidates, ablation therapies destroy the tumor without removing it:
- Cryoablation: Freezes the tumor using extreme cold delivered through a needle inserted into the tumor under imaging guidance.
- Radiofrequency ablation (RFA): Uses high-energy radio waves to heat and destroy the tumor.
These minimally invasive options are typically reserved for smaller tumors and are performed under imaging guidance (CT or ultrasound). While effective for small tumors, they may carry a somewhat higher local recurrence rate compared with surgery, so follow-up imaging is important.
Systemic Therapies for Advanced Kidney Cancer
When kidney cancer has spread beyond the kidney (Stage IV) or has returned after initial treatment, systemic therapies that work throughout the body are the primary approach. The treatment of advanced kidney cancer has been transformed in recent years, and this is where much of the improvement in outcomes has come from. What was once a disease with few effective options is now treated with powerful immune and targeted therapies that can control the cancer for years in many patients.
Immunotherapy
Immunotherapy has become a cornerstone of treatment for advanced kidney cancer. These drugs help the immune system recognize and attack cancer cells:
- Immune checkpoint inhibitors: Drugs such as nivolumab (Opdivo), pembrolizumab (Keytruda), and ipilimumab (Yervoy) work by blocking proteins that hold immune cells back, unleashing them against the cancer. The combination of nivolumab and ipilimumab was shown in the CheckMate 214 trial to significantly improve overall survival compared with older targeted therapy alone in intermediate- and poor-risk patients.
- Immunotherapy plus targeted therapy: Regimens combining a checkpoint inhibitor with a targeted drug (for example, pembrolizumab plus axitinib or lenvatinib, or nivolumab plus cabozantinib) have become standard first-line treatment for many patients with advanced RCC, consistent with National Comprehensive Cancer Network (NCCN) guidelines. These combinations have produced meaningful gains in survival and response.
Importantly, a subset of patients treated with immunotherapy-based regimens achieve deep, durable responses that last for years, and a small number achieve complete responses. This is a major reason for optimism that did not exist a generation ago.
Targeted Therapy
Targeted therapy drugs interfere with specific molecular pathways that kidney cancer cells rely on to grow and survive:
- VEGF/VEGFR (TKI) inhibitors: Drugs like sunitinib, pazopanib, cabozantinib, axitinib, and lenvatinib block the formation of new blood vessels that tumors need to grow. These tyrosine kinase inhibitors have been a mainstay of advanced kidney cancer treatment for over a decade and are frequently paired with immunotherapy today.
- mTOR inhibitors: Everolimus and temsirolimus target a protein involved in cell growth and division and are typically used in later lines of treatment.
- HIF-2 alpha inhibitor: Belzutifan (Welireg) targets the HIF-2 alpha pathway, which is abnormally active in many kidney cancers, and is FDA-approved for certain patients with advanced RCC, including some with von Hippel-Lindau disease.
Because these drugs and their approved uses continue to evolve, your oncologist will select and sequence them based on the most current evidence and your tumor’s features. This article provides no dosing; medication choices, doses, and schedules are set and adjusted only by your treating team.
Cytoreductive Nephrectomy
In some cases of metastatic kidney cancer, surgeons may remove the primary kidney tumor even though cancer has spread elsewhere. This cytoreductive nephrectomy can benefit selected patients, though its role has become more nuanced in the era of immunotherapy-based regimens and is decided case by case by a multidisciplinary team.
Radiation Therapy
Kidney cancer cells are relatively resistant to conventional radiation, so radiation therapy is not a primary treatment for the kidney tumor itself. However, modern focused techniques play valuable roles in specific situations:
- Treating brain metastases (stereotactic radiosurgery)
- Relieving pain from bone metastases
- Managing symptoms from tumors that cannot be surgically removed
- Stereotactic body radiation therapy (SBRT) for selected tumors in patients who cannot have surgery
Choosing a Treatment: What to Consider
Treatment decisions for kidney cancer involve several factors:
- Cancer stage and subtype: The most important determinant of treatment approach
- Overall health and fitness: Surgical candidates need adequate physical fitness for recovery
- Kidney function: Preserving kidney function is prioritized when possible
- Molecular and genetic features: Some tumors have characteristics that guide therapy selection, and inherited syndromes may change the plan
- Patient preferences: Quality of life considerations, treatment side effects, and personal values
Seek care from a multidisciplinary team that includes a urologist or urologic oncologist, a medical oncologist, and, when appropriate, a radiation oncologist — ideally at a cancer center that treats kidney cancer regularly. Coordinated, specialized care is associated with better decision-making and access to the newest options. For help locating a specialist, see our guide on how to find an oncologist.
Clinical Trials
Clinical trials offer access to cutting-edge treatments that are not yet widely available. The NIH clinical trials database (ClinicalTrials.gov) lists many active kidney cancer trials testing new drugs, combinations, and approaches. Discuss clinical trial eligibility with your oncologist, particularly if standard treatments have not been effective or if you have a rare subtype. Trials are a legitimate treatment option, not a last resort, and some patients access tomorrow’s therapies this way.
When to See a Doctor
- Blood in the urine (hematuria), even if intermittent
- Persistent pain in the side, flank, or lower back not caused by injury
- An unexplained lump or mass in the abdomen or flank area
- Unexplained weight loss, fatigue, or fever
- Recurrent urinary tract infections
- Swelling in the legs or ankles
Many kidney cancers are found incidentally during imaging for other conditions. These symptoms have many possible causes and do not necessarily mean cancer, but they should be evaluated promptly. If you have been diagnosed, consider a second opinion at a comprehensive cancer center, particularly for advanced-stage disease.
Frequently Asked Questions
Can kidney cancer be cured?
Yes, kidney cancer that is detected early (Stage I or II) and treated with surgery has a high cure rate; the five-year survival rate for localized kidney cancer is well over 90 percent. For advanced kidney cancer that has spread to distant organs, a cure is less likely, but long-term disease control is increasingly achievable with modern immunotherapy and targeted therapy combinations. Some patients with metastatic disease achieve deep, durable responses that last for years.
What is the survival rate for kidney cancer?
According to the American Cancer Society, the overall five-year relative survival rate for kidney cancer across all stages is roughly three-quarters, and it is higher for localized disease and lower for distant disease. These figures are drawn from large historical databases and are improving as newer treatments become widely used, so ask your care team how current data apply to your case.
What are the side effects of kidney cancer treatment?
Side effects depend on the treatment type. Surgery involves typical surgical risks (pain, infection, bleeding) plus potential impact on kidney function. Immunotherapy can cause immune-related side effects affecting the skin, gut, liver, lungs, or endocrine (hormone) system, which need prompt attention. Targeted therapy commonly causes fatigue, diarrhea, high blood pressure, hand-foot syndrome, and thyroid dysfunction. Your oncology team will monitor and manage side effects throughout treatment.
Is chemotherapy used for kidney cancer?
Traditional chemotherapy is generally not effective against renal cell carcinoma and is rarely used. Kidney cancer cells have mechanisms that make them resistant to most chemotherapy drugs. Instead, immunotherapy and targeted therapy have become the standard systemic treatments for advanced kidney cancer. Chemotherapy may occasionally be used for rare subtypes, such as collecting duct carcinoma.
How long does kidney cancer treatment take?
The timeline varies by treatment type. Surgery requires several weeks of recovery for most patients. Systemic therapies for advanced disease are typically continued for as long as they are working and tolerable, which can be months to years. Immunotherapy is sometimes given for a defined period if the cancer responds well, or until the disease progresses. Your oncologist will establish a treatment and monitoring plan tailored to your situation.
Practical Takeaway
Treatment for kidney cancer has advanced significantly, offering effective options at every stage of the disease. Early-stage cancers are often curable with surgery alone, while advanced cancers now benefit from powerful immunotherapy and targeted therapy combinations that can extend survival and improve quality of life. Work with a specialized oncology team, consider seeking care at a comprehensive cancer center, and discuss clinical trial options, especially for advanced disease. The most important steps are getting diagnosed accurately, staged completely, and connected with experienced specialists who can guide your treatment journey with both expertise and compassion. For more information on health conditions and treatment, visit our medical conditions guide.
TL;DR: Treatment for kidney cancer depends on stage. Localized tumors are usually treated with surgery (partial or radical nephrectomy), ablation, or active surveillance for small tumors. Advanced or metastatic renal cell carcinoma is treated with systemic therapy, where immunotherapy (immune checkpoint inhibitors) — frequently combined with targeted therapy — is now standard first-line care and has substantially improved outcomes, sometimes producing durable, years-long responses. Care is best delivered by a multidisciplinary team led by a urologist and medical oncologist, ideally at a cancer center. See a doctor promptly for blood in the urine, persistent flank pain, or an abdominal mass.
This article is for general education only and is not medical advice. It provides no drug dosing and cannot replace evaluation and treatment planning by a qualified oncology team. Treatment must be individualized; discuss your options, the latest evidence, and clinical trials with your doctors.
Sources
- American Cancer Society — Kidney Cancer (key statistics, staging, and survival rates)
- National Cancer Institute — Renal Cell Cancer Treatment (PDQ)
- National Comprehensive Cancer Network (NCCN) — Clinical Practice Guidelines for Kidney Cancer (first-line immunotherapy-based combinations)
- NIH / ClinicalTrials.gov — active kidney cancer clinical trials